1. Sirolimus in Refractory Cronkhite-Canada Syndrome and Focus on Standard Treatment
- Author
-
Catherine Langevin MD, Hugo Chapdelaine MD, Jean-Maxime Picard MD, Pierre Poitras MD, and Raymond Leduc MD, FRCPC
- Subjects
Medicine (General) ,R5-920 ,Pathology ,RB1-214 - Abstract
Cronkhite-Canada syndrome is a rare syndrome consisting of extensive gastrointestinal polyposis and ectodermal changes including cutaneous hyperpigmentation, alopecia, and onychodystrophy. We report the case of a 45-year-old Caucasian male patient who failed multiple treatments over 2 years including steroids, azathioprine, adalimumab, and cyclosporine. He had recurrent and prolonged hospitalizations because of diarrhea, abdominal pain, weight loss, and malnutrition. Sirolimus was initiated with a significant clinical and endoscopic benefit apparent within, respectively, 2 and 8 weeks. An ongoing remission was achieved and maintained for over 6 months after prednisone tapering. We review the current evidence on treatment of Cronkhite-Canada syndrome and suggest the incorporation of sirolimus in that algorithm.
- Published
- 2018
- Full Text
- View/download PDF